

Novel Treatment for Bystander Cell Death

a presentation by Jay Chaplin of Institute for Applied Biomedicine

HIV appears to cause T cell death without infecting cells, as well as through direct infection. The mechanism by which HIV kills uninfected, or “bystander,” cells is outlined in this poster. Institute for Applied Biomedicine is an independent 501(c)(3) non-profit research organization and is researching a novel, immune-system-based treatment for bystander cell death in AIDS.

The references listed below provide more information about the topics which are presented only briefly in this poster. The poster itself and this list of references will be available for downloading on the website at www.appliedbiomed.org, which also includes a copy of Chaplin’s paper on this work, “HIV Pathogenesis,” from *Medical Hypotheses* (February 1999). You can reach the Institute in e-mail at info@appliedbiomed.org or by phone at 831-454-9147 with any questions.

Panel 1: HIV’s Interaction with the Immune System

- Hart, T., Klinkner, A., Ventre, J., and Bugelski, P. 1993. Morphometric analysis of envelope glycoprotein gp120 distribution on HIV-1 virions. *J. Histochem. and Cytochem.* 41:265-271

Moore, J., McKeating, J., Weiss, R., and Sattenau, Q. 1990. Disassociation of gp120 from HIV-1 virions induced by soluble CD4. *Science.* 250:1139-1142

Poignard, P., Fouts, T., Nanche, D., Moore, J., and Sattentau, Q. 1996. Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit disassociation. *J. Exp.Med.* 183:473-484
- Oh, S., Cruikshank, W., Raina, J., et al. 1992. Identification of HIV-1 envelope glycoprotein in the serum of AIDS and ARC patients. *J. AIDS.* 5:251-256
- McDougal, J., Kennedy, M., Sligh, J., Cort, S., Mawle, A., and Nicholson, J. 1986. Binding of HTLV-III/LAV to T4+ cells by a complex of the 110K viral protein and the T4 molecule. *Science.* 231:382-385

Finbloom, D., Hoover, D., and Meltzer, M. 1991. Binding of recombinant HIV coat protein gp120 to human monocytes. *J. Immunol.* 146:1316-1321

Schnittman, S., Lane, H., Roth, J., et al. 1988. Characterization of gp120 binding to CD4 and an assay that measures ability of sera to inhibit this binding. *J. Immunol.* 141:4181-4186
- Martinez-Maza, O., Crabb, E., Mitsuyasu, R., Fahey, J., and Giorgi, J. 1987. Infection with the human immunodeficiency virus (HIV) is associated with an in vivo increase in B lymphocyte activation and immaturity. *J. Immunol.* 138:3720-3724
- Skowron, G., Cole, B., Zheng, D., Acetta, G., and Yen-Lieberman, B. 1997. gp120-directed antibody-dependent cellular cytotoxicity as a major determinant of the rate of decline in CD4 percentage in HIV-1 disease. *AIDS* 11:1807-1814

Gerencer, M., Burek, V., Crowe, B., Barrett, N., and Dorner, F. 1998. The role of complement and gp120-specific antibodies in virus lysis and CD4+ T cell depletion in HIV-1-infected patients. *Microb. Path.* 25:253-

Hober, D., Jewett, A., and Bonavida, B. 1995. Lysis of uninfected HIV-1 gp120-coated peripheral blood-derived T lymphocytes by monocyte-mediated antibody-dependant cellular cytotoxicity. *FEMS Immunol. and Med. Microbiol.* 10:83-92

Lyerly, H., Reed, D., Matthews, T., et al. 1987. Anti-gp120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC. *AIDS Res. and Hum. Retro.* 4:409-422

Weinhold, K., Lyerly, H., Stanley, S., Austin, A., Matthews, T., and Bolognesi, D. 1989. HIV-1 gp120-mediated immune suppression and lymphocyte destruction in the absence of viral infection. *J. Immunol.* 142:3091-3097

Bystander cell death insert

Pantaleo, G., Graziosi, C., Demarest, J., et al. 1993. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. *Nature.* 362:355-358

Adachi, Y., Oyaizu, N., Than, S., McCloskey, T.W., and Pahwa, S. 1996. IL-2 rescues in vitro lymphocyte apoptosis in patients with HIV infection. *J. Immunol.* 157:4184-4193

Finkel, T., Tudor-Williams, G., Banda, N., et al. 1995. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. *Nat. Med.* 1:129-134

Laurent-Crawford, A., Krust, B., Muller, S., et al. 1991. The cytopathic effect of HIV is associated with apoptosis. *Virology.* 185:829-839

Panel 2 : Cell Signalling Defects

Amadori, A., DeSilvestro, G., Zamarchi, R., et al. 1992. CD4 epitope masking by gp120/anti-gp120 antibody complexes. *J. Immunol.* 148:2709-2716

Newell, M., Haughn, L., Maroun, C., and Julius, M. 1990. Death of mature T cells by separate ligation of CD4 and the T-cell receptor for antigen. *Nature.* 347:286-289

Banda, N., Bernier, J., Kurahara, D., et al. 1992. Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis. *J. Exp. Med.* 176:1099-1106

Foster, S., Beverley, P., and Aspinall, R. 1995. gp120-induced programmed cell death in recently activated T cells without subsequent ligation of the T cell receptor. *Eur. J. Immunol.* 25:1778-1782

Juszczak, R., Turchin, H., Truneh, A., et al. 1991. Effect of human immunodeficiency virus gp120 glycoprotein on the association of the protein tyrosine kinase p56lck with CD4 in human T lymphocytes. *J. Biol. Chem.* 266:11176-11183

Di Somma, M., Nuti, S., Telford, J., et al. 1995. p56lck plays a key role in transducing apoptotic signals in T cells. *FEBS lett.* 363:101-104

Jabado, N., Le Deist, F., Fischer, a., and Hivroz, C. 1994. Interaction of HIV gp120 and anti-CD4 antibodies with the CD4 molecule on human CD4+ cells inhibits the binding activity of NF-AT, NF-kB and AP-1, three nuclear factors regulating interleukin-2 gene enhancer activity. *Eur. J. Immunol.* 24:2646-2652

Therapeutic uses insert

Arima, T., Lehmann, M., and Flye, M. 1997. Induction of donor specific transplantation tolerance to cardiac allografts following treatment with nondepleting (RIB 5/2) or depleting (OX-38) anti-CD4 mAB plus intrathymic or intravenous donor alloantigen. *Transplantation*. 63:284-292

Vincent, C., Fournel, S., Wijdenes, J., and Revillard, J. 1995. Specific hyporesponsiveness of alloreactive peripheral T cells induced by CD4 antibodies. *Eur. J. Immunol.* 25:816-822

Panel 3: B Cell Clonal Toxin to Eliminate Antibodies

Kang, Y., Melo, M., Scott, D. 1998. An ongoing immune response to HIV envelope gp120 in human CD4-transgenic mice contributes to T cell decline upon intravenous administration of gp120. *Eur. J. Immunol.* 28:2253-2264

Finco, O., Nuti, S., De Magistris, M. T., et al. 1997. Induction of CD4+ T cell depletion in mice doubly transgenic for HIV gp120 and human CD4. *Eur. J. Immunol.* 27:1319-1324

Muller, C., Kukel, S., and Bauer, R. 1993. Relationship of antibodies against CD4+ T cells in HIV-infected patients to markers of activation and progression: autoantibodies are closely correlated with CD4 cell depletion. *Immunology*. 79:248-254

Daniel, V., Susal, C., Weimer, R., Zimmerman, R., Huth-Kuhne, A., and Opelz, G. 1993. Association of T cell and macrophage dysfunction with surface gp120-immunoglobulin-complement complexes in HIV-infected patients. *Clin. Exp. Immunol.* 93:152-156

Wang, Z., Orlikowsky, T., Dudhane, A., et al. 1994. Deletion of T lymphocytes in human CD4 transgenic mice induced by HIV-gp120 and gp120-specific antibodies from AIDS patients. *Eur. J. Immunol.* 24:1553-1557

Action of Diphtheria toxin

Murphy, J., and Strom, T. 1990. Diphtheria toxin-peptide hormone fusion proteins: protein engineering and selective action of a new class of recombinant biological response modifiers in ADP-ribosylating toxins and G proteins. J. Moss and M. Vaughan, eds. *American Society of Microbiologists*. Washington D.C. P. 141-160

Choe, S., Bennett, M., Fuji, G., et al. 1992. The crystal structure of Diphtheria toxin. *Nature*. 357:216-357

Thymocyte insert

Anderson, S., and Perlmutter, R. 1995. A signalling pathway governing early thymocyte maturation. *Immunology Today*. 16:99-105

Amadori, A., DeSilvestro, G., Zamarchi, R., et al. 1992. CD4 epitope masking by gp120/anti-gp120 antibody complexes. *J. Immunol.* 148:2709-2716

IL-2 reversibility

Schols, D., and De Clercq, E. 1996. Human immunodeficiency virus type 1 gp120 induces anergy in human peripheral blood lymphocytes by inducing interleukin-10 production. *J. Virol.* 70:4953-4960

Oyaizu, N., Chirmule, N., Kalyanaraman, V., Hall, W., Good, R., and Pahwa, S. 1990. Human immunodeficiency virus type 1 envelope glycoprotein gp120 produces immune defects in CD4+ T lymphocytes by inhibiting interleukin 2 mRNA. *Proc. Natl. Acad. Sci. USA* 87:2379-2383

Panel 4: Drug Design

Ada, G.L., and P. Byrt. 1969. Specific inactivation of antigen-reactive cells with I125-labeled antigen. *Nature*. 222:1291-1293

gp120 binding site mutations insert

Olshevsky, U., Helseth, E., Furman, C., Li, J., Haseltine, W., and Sodroski, J. 1990. Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. *J. Virol.* 64:5701-5707

Matthews, T., Weinhold, K., Lyerly, H., Langlois, A., Wigzell, H., and Bolognesi, D. 1987. Interaction between human T-cell lymphotropic virus type III_B envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion. *Proc. Natl. Acad. Sci.* 84:5424-5428

Receptorless diphtheria toxin insert

Murphy, J., and Strom, T. 1990. Diphtheria toxin-peptide hormone fusion proteins: protein engineering and selective action of a new class of recombinant biological response modifiers in ADP-ribosylating toxins and G proteins. J. Moss and M. Vaughan, eds. *American Society of Microbiologists*. Washington D.C. P. 141-160

Greenfield, L., Johnson, V., and Youle, R. 1987. Mutations in Diphtheria toxin separate binding from entry and amplify immunotoxin activity. *Science*. 238:536-539

Williams, D., Snider, C., Strom, T., and Murphy, J. 1990. Structure/function analysis of interleukin-2-toxin (DAB₄₈₆-IL-2). *J. Biol. Chem.* 265:11885-11889

Yamaizumi, M., Mekada, E., Uchida, T., and Okada, Y. 1978. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. *Cell*. 15:245-250